Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInvestment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Abivax (ABVX) EBITDA: 2021-2024

Historic EBITDA for Abivax (ABVX) over the last 4 years, with Dec 2024 value amounting to -$184.8 million.

  • Abivax's EBITDA fell 38.85% to -$52.4 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$139.7 million, marking a year-over-year decrease of 62.14%. This contributed to the annual value of -$184.8 million for FY2024, which is 34.88% down from last year.
  • As of FY2024, Abivax's EBITDA stood at -$184.8 million, which was down 34.88% from -$137.0 million recorded in FY2023.
  • Abivax's 5-year EBITDA high stood at -$49.0 million for FY2021, and its period low was -$184.8 million during FY2024.
  • Its 3-year average for EBITDA is -$130.1 million, with a median of -$137.0 million in 2023.
  • Data for Abivax's EBITDA shows a maximum YoY slumped of 100.56% (in 2023) over the last 5 years.
  • Abivax's EBITDA (Yearly) stood at -$49.0 million in 2021, then crashed by 39.48% to -$68.3 million in 2022, then tumbled by 100.56% to -$137.0 million in 2023, then slumped by 34.88% to -$184.8 million in 2024.